EUCTR2021-001424-17-SK进行中（未招募）1 期
A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-CF113 in the treatment of endometriosis versus placebo after 3 medication cycles followed by 3 open-label medication cycles
Chemo Research S. L.0 个研究点目标入组 236 人开始时间: 2021年6月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 236
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Postmenarcheal and premenopausal female subjects = 15 and = 45 years of age at screening, not seeking pregnancy.
- •2. Endometriosis was diagnosed by laparoscopy at least 6 weeks before Visit 1a and either
- •a. histological confirmation was documented, OR
- •b. in cases where histological confirmation is not available, the complete laparoscopy report with a visual confirmation of the diagnosis is available to the investigator.
- •3. EAPP of = 3 points on an NRS during the last 3 months before screening.
- •4. Be able and willing to provide written informed consent or assent before any trial-related procedure will be performed.
- •5. In females not using a hormonal contraceptive at screening: regular menstrual cycles (i.e. cycle length between 21 and 35 days) during the last 3 months before screening.
- •6. Willing to agree to one wash-out cycle of hormonal therapies, if applicable.
- •7. Willing to use one agreed NSAID or paracetamol as rescue medication throughout the trial. No switching or start of an additional pain killer should be planned after Visit 1a until the end of the trial.
- •8. Systolic blood pressure = 140 mmHg and diastolic blood pressure = 90 mmHg at screening, in a sitting position after 5 minutes of rest.
- •9. Willing to use IP for six 28-day cycles.
- •10. Willing to use reliable non-hormonal contraceptive methods (condoms, female or male sterilisation or sexual abstinence [if in line with the preferred and usual lifestyle of the subject]) during the course of the trial.
- •11. Be in good physical (apart from endometriosis) and mental health according to medical history and general physical examination performed at screening.
- •12. Willing to adhere to the prohibitions and restrictions specified in the protocol.
- •13. Agree not to participate in any other clinical trials during the course of this trial.
- •Inclusion criteria at Visit 1b:
- •14. Have completed the e-diary in accordance with the e-diary instructions and with no more than 1 missed entry per each week during the last 28 days before Visit 1b.
- •15. Have regular menstrual cycles (i.e. cycle length between 21 and 35 days) during the screening period.
- •16. A mean EAPP score of = 3 points on an NRS within the last 28 days before Visit 1b as assessed by e-diary entries.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 226
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Ongoing pregnancy, wish for pregnancy, and breastfeeding subjects.
- •2. Subject is known to or suspected of not being able to comply with the trial protocol, the use of IP or trial e-diary.
- •3. Abnormal finding on pelvic, breast or ultrasound examination other than those related to endometriosis that in the investigator’s opinion contraindicates participation in the trial.
- •4. Pelvic pain not caused by endometriosis (e.g. interstitial cystitis, presumptive adenomyosis, fibroids, post-surgery pain, etc.). In case of a recent ( < 3 months prior to Visit 1a) surgery, incl. low invasive laparoscopy, the investigator should confirm that the subject has fully recovered.
- •5. Any other pathology associated with chronic pain (e.g. fibromyalgia, chronic back pain, chronic headaches, etc.).
- •6. Laboratory values, heart rate and/or electrocardiogram assessment at screening which are considered clinically significant and which in the opinion of the investigator would be detrimental for participation in the trial.
- •7. Known contraindication to the use of LPRI-CF113:
- •a) Active venous thromboembolic disorder.
- •b) Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
- •c) Severe renal insufficiency or acute renal failure.
- •d) Known or suspected sex-steroid sensitive malignancies.
- •e) Undiagnosed vaginal bleeding.
- •f) Hypersensitivity to the active substance or to any of the excipients.
- •8. Currently ongoing conditions or previous history of:
- •a) Cerebral-vascular or coronary-artery disease which includes myocardial infarction, angina pectoris.
- •b) Valvular heart disease with thrombogenic complications.
- •c) Headaches with focal neurological symptoms.
- •d) Known or suspected carcinoma of the breast.
- •e) Arterial and cardiovascular disease, past or present (e.g. myocardial infarction, cerebrovascular accident, ischemic heart disease).
- •f) Diabetes mellitus with vascular involvement.
- •g) Adrenal insufficiency.
- •h) History of cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use.
- •i) Hyperkalaemia.
- •j) Hysterectomy.
- •9. Major surgery with more than 7 days of immobilisation within the 2 weeks prior to screening.
- •10. Uncontrolled concomitant diseases (i.e. not on a stable treatment dose for at least 2 months before screening).
- •11. Evidence or history of alcohol, medication or drug abuse (within the last 12 months prior to screening).
- •12. Known or suspected human immunodeficiency virus (HIV) and/or hepatitis infection at screening.
- •13. Received a dose of depot medroxyprogesterone acetate (DMPA or Depo-Provera®) within the last 10 months prior to screening, or received any combined injectable contraceptive (e.g. Cyclofem®) within the last 6 months prior to screening, or no spontaneous menses since last injection.
- •14. Long-term treatment (> 7 consecutive days within a month prior to Visit 1b) of any medication that might interfere with the efficacy of hormonal contraceptives, e.g.:
- •a) Anticonvulsants (e.g. phenytoin, carbamazepine, oxcarbazepine, topiramate, felbamate, primidone, lamotrigine)
- •b) Potent inhibitors of CYP3A4 (fluconazole, ketoconazole, itraconazole or voriconazole).
- •c) Barbiturates
- •d) Antibiotics (such as rifampicin)
- •e) HIV medication (such as ritonavir, nelfinavir, neviparine and efavirenz)
- •f) Hepatitis C virus (HCV) medication (e.g. boceprevir, telaprevir)
- •g) Macrolides (clarithromycin and erythromycin)
- •h) Bosentan
- •i) Griseofulvin
- •j) Verapamil
- •k) Diltiazem
- •l) Cyclosporin
研究者
相似试验
进行中（未招募）
1 期
Ivermectin to prevent SARS-CoV-2 (COVID-19) hospitalisation in subjects over 50EUCTR2020-005015-40-SKChemo Research S.L.832
进行中（未招募）
1 期
A clinical study in women suffering from polycystic ovary syndrome (PCOS) to test the drug LPRI-424 (dinogest/ethinyl estradiol) during 9 months of treatmentEUCTR2021-002178-17-CZChemo Research S.L.367
进行中（未招募）
1 期
A clinical study in women suffering from endometriosis to test the drug LPRI-CF113 (drospirenone) during 6 months of treatmentEndometriosisEUCTR2021-001424-17-HUChemo Research S. L.236
进行中（未招募）
1 期
A clinical study in women suffering from endometriosis to test the drug LPRI-CF113 (drospirenone) during 6 months of treatmentMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2021-001424-17-LTChemo Research S. L.236
进行中（未招募）
1 期
A clinical study in women suffering from endometriosis to test the drug LPRI-CF113 (drospirenone) during 6 months of treatmentMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2021-001424-17-CZChemo Research S. L.236